Investor Presentaiton
Investor presentation
Full year 2018
Biopharm constitutes 16% of Novo Nordisk sales and the
'return to growth' strategy is well on track
bDKK
25
20
NovoSevenⓇ and NorditropinⓇ
account for 82% of Biopharm sales¹
Other biopharmaceuticals
Other haemophilia products
NorditropinⓇ
NovoSevenⓇ
Slide 37
'Return to Growth' strategy builds on organic,
non-organic and organisational initiatives
180
Drive in-market brands and
ensure successful pipeline
launches
15
10
5
10
0
2014
2015
2016
2017
2018
1 Reported sales for 2018
changing
diabetes
Return to
growth
in Biopharm
Pursue licensing or acquisition of
complementary assets or
companies
Strengthen the organisation to
drive the Biopharm 'return to
growth'-agenda
novo nordiskView entire presentation